H.C. Wainwright lowers Nurix Therapeutics (NRIX) price target to $34 from $36, maintains Buy rating. Q2 net loss of (52c) per share reported, slightly narrower than previously estimated. Firm expects greater operating expenses moving forward.

For more breaking financial news, visit TheFly – the ultimate source for real-time, market-moving updates.

To see today’s best-performing stocks, check out TipRanks.

Disclaimer & Disclosure: Report any issues to the editor.

Read more at Yahoo Finance: Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright